Bicara Therapeutics Inc. (NASDAQ:BCAX) Forecasted to Post FY2024 Earnings of ($1.61) Per Share

Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2024 earnings per share estimates for shares of Bicara Therapeutics in a research report issued to clients and investors on Tuesday, October 8th. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will post earnings of ($1.61) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock.

Several other equities analysts have also issued reports on BCAX. TD Cowen began coverage on Bicara Therapeutics in a report on Tuesday. They issued a "buy" rating for the company. Morgan Stanley began coverage on Bicara Therapeutics in a report on Tuesday. They issued an "overweight" rating and a $35.00 target price for the company. Finally, Stifel Nicolaus began coverage on Bicara Therapeutics in a report on Tuesday. They issued a "buy" rating and a $47.00 target price for the company.

Bicara Therapeutics Price Performance

BCAX traded down $1.30 during midday trading on Thursday, reaching $19.00. 844,928 shares of the company were exchanged, compared to its average volume of 398,501. Bicara Therapeutics has a one year low of $18.58 and a one year high of $27.94.

Insider Activity at Bicara Therapeutics

In other news, major shareholder James E. Flynn acquired 70,000 shares of the company's stock in a transaction that occurred on Tuesday, September 17th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the purchase, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, major shareholder James E. Flynn acquired 70,000 shares of the company's stock in a transaction that occurred on Tuesday, September 17th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the purchase, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the company's stock in a transaction that occurred on Monday, September 16th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the purchase, the director now owns 4,303,418 shares of the company's stock, valued at $77,461,524. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.